ROLE OF CYTOCHROME P450 3A4 IN THE METABOLISM OF DRUGS USED TO TREAT CHRONIC HEART FAILURE

Download full text PDF
Issue: 
9
Year: 
2016

A. Zhestovskaya (1), V. Smirnov (1,3), Candidate of Pharmaceutical Sciences; Professor A. Prokofyev (1,3), MD; Professor V. Kukes (1), Academician of the Russian Academy of Sciences; Professor D. Sychev (2), MD 1 -I.M. Sechenov First Moscow State Medical University 2 -Russian Medical Academy of Postgraduate Education, Moscow 3 -Research Center for Examination of Medical Products, Ministry of Health of the Russian Federation, Moscow

The investigation has shown that a change in CYP3A4 activity may have clinical consequences if a CYP3A4-metabolized drug is used at average therapeutic doses.

Keywords: 
renin-angiotensin-aldosterone system
cytochrome P450 3A4
aldosterone
metabolism
chronic heart failure



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Marrel R., Grenner D., Mejs P. i dr. Biohimija cheloveka. T. 2, Per. s angl. / M.: Mir, 2004.
  2. Kukes V.G. Funktsional'noe sostojanie nekotoryh nejroendokrinnyh sistem u bol'nyh s hronicheskoj nedostatochnost'ju krovoobraschenija (mate-rialy klinicheskih, funktsional'nyh, biohimicheskih, radioizotopnyh i morfologicheskih metodov issledovanija). Dis. … d-ra med. nauk. M., 1970.
  3. Kashaeva O.V. Sostojanie metabolicheskoj funktsii pecheni i optimiza tsija farmakoterapii u bol'nyh hronicheskoj serdechnoj nedostatochnost'ju. Avtoref. dis. ... kand. med. nauk. M., 2002; 19 s.
  4. Ramenskaja G.V. Hromatograficheskoe opredelenie lekarstvennyh sredstv i ih metabolitov dlja fenotipirovanija izofermentov tsitohroma P450 // Himiko-farmatsevticheskij zhurnal: nauchno-tehnicheskij i proizvod-stvennyj zhurnal. – 2005; 39 (2): 53–6.
  5. Sherlock S., Dick R., Van Leeuwen D. Liver biopsy today. The Royal Free Hospital experience // J. Hepatol. – 1985; 1 (1): 75–85.
  6. Johnston D., Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure // Am. J. Cardiol. – 1992; 70 (10): 109–12.
  7. Berkowitz D. The differential diagnosis of the coronary artery disease and gastrointestinal disorders // Am. J. Cardiol. – 1963; 12: 354–7.
  8. Higgins C., Vatner S., Braunwald E. Postprandial redistribution of regional blood flow at rest and during exercise in conscious dogs with experimental hear
  9. Shumjantseva V.V., Mahova A.A., Bulko T.V. i dr. Vlijanie antioksidan tov na elektrokataliticheskuju aktivnost' tsitohroma R450 3A4 // Biomed. Himija. – 2014; 60 (2): 224–34.
  10. Archakov A., Bachmanova G. Cytochrome P450 and Active Oxygen / 1 London: Taylor and Francis, 1990.
  11. Mahova A.A., Shumjantseva V.V., Shih E.V. i dr. Reguljatsija aktivnosti 20. fermentov metabolizma lekarstvennyh preparatov – tsitohromov R450 3A4 i 2S9 – biologicheski aktivnymi soedinenijami // Molekuljarnaja meditsina. – 2013; 5: 49–53.
  12. Otdelenov V.A., Smirnov V.V., Dmitriev A.V. i dr. Vlijanie etilmetil gidroksipiridinamalata na aktivnost' CYP3A4: kompleksnyj podhod k otsenke vlijanija na sistemu biotransformatsii lekarstvennyh sredstv // Lekarstvennye preparaty i ratsional'naja farmakoterapija. – 2013; 3: 30–6.
  13. Kattsung-Bertram G. Bazisnaja i klinicheskaja farmakologija. T. 1 / SPb: 22. Nevskij Dialekt, 1998; s. 73–86
  14. Manujlov V.G., Luchkevich V.S., Rumjantsev A.P. i dr. Osnovy nauchnolite raturnoj raboty v meditsine / SPb: SPbGMA im. I.I. Mechnikova, 1996; 125.
  15. Felix C., Walker A., Lange B. et al. Association of CYP3A4 genotype with 24. treatment-related leukemia // Proc. Natl. Acad. Sci. USA. – 1998; 95 (22): 13176–81.
  16. Kukes V., Sychev D., Ramenskaja V. i dr. Otsenka aktivnosti izofermenta tsitohroma R450 3A4 (CYP3A4) kak real'naja vozmozhnost' personalizatsii farmakoterapii // Vrach. – 2008; 3: 13–9. t failure // Am. J. Cardiol. – 1974; 34 (3): 318–24.
  17. Zelis R., Nellis S., Longhurst J. et al. Abnormalities in the regional . circulations accompanying congestive heart failure // Prog. Cardiovasc. Dis. – 1975; 18 (3): 181–99.
  18. Partharasarathy H., Menard J., White W. et al. A double-blind randomized . study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism // J. Hypertens. – 2011; 29: 980–90.
  19. Sychev D.A., Ramenskaja G.V., Ignat'ev I.V. i dr. Klinicheskaja farma kogenetika. Pod red. V.G. Kukesa, N.P. Bochkova / M.: GEOTAR-Media, 2007; 248 s.
  20. Luk'janova L.D. Sovremennye problemy i perspektivy farmakologi-12. cheskoj korrektsii gipoksicheskih sostojanij. V kn.: Farmakoterapija v nevro-logii i psihiatrii / M., 2002; s. 22–34.
  21. Smirnov A.V., Krivoruchko B.I. Antigipoksanty v neotlozhnoj meditsi-13. ne // Anesteziologija i reanimatologija. – 1998; 2: 50–5.
  22. Luk'janchuk V.D., Savchenkova L.V. Antigipoksanty: sostojanie i perspek-14. tivy // Eksperim. i klin. farmakol. – 1998; 61 (4): 72–9.
  23. Negovskij V.A., Zolotokrylina E.S. Postreanimatsionnaja bolezn' / M.: 15. Meditsina, 1987; 480.
  24. Luk'janova L.D. Novye podhody k sozdaniju antigipoksantov metabo-16. licheskogo dejstvija // Vestnik RAMN. – 1999; 3: 18–25.
  25. Stoljarova V.V. Issledovanie kardioprotektornogo dejstvija prepara-17. tov s antioksidantnoj aktivnost'ju pri ostroj ishemii golovnogo mozga // Eksperim. i klin. farmakol. – 2001; 64 (6): 31–3.